Maprotiline
Maprotiline, sold under the brand name Ludiomil among others, is a tetracyclic antidepressant (TeCA) that is used in the treatment of depression. It may alternatively be classified as a tricyclic antidepressant (TCA), specifically a secondary amine. In terms of its chemistry and pharmacology, maprotiline is closely related to such-other secondary-amine TCAs as nortriptyline and protriptyline and has similar effects to them, albeit with more distinct anxiolytic effects. Additionally, whereas protriptyline tends to be somewhat more stimulating and in any case is distinctly more-or-less non-sedating, mild degrees of sedation may be experienced with maprotiline.
Clinical data | |
---|---|
Trade names | Ludiomil, others |
Other names | Maprotiline hydrochloride; Maprotiline methanesulfonate; Ba 34276 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682158 |
Routes of administration | Oral, intramuscular, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 66–70% |
Protein binding | 88% |
Metabolism | hepatic |
Onset of action | 6 hours |
Elimination half-life | 27–58 hours |
Excretion | Urine (57%) and bile (30%) as glucuronides, 3–4% as unchanged drug |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.030.532 |
Chemical and physical data | |
Formula | C20H23N |
Molar mass | 277.411 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.